Resistance to cetuximab in CRC is mediated by activation of compensatory pathways through modulation of microRNAs to adapt and survive under EGFR inhibition, e.g., through upregulation of miR-199a-5p and miR-375, which target PHLPP1 [55], upregulation of miR-100 and miR-125b via activation of Wnt/β-catenin signaling [56], or downregulation of miR-302a, which targets NFIB and CD44 [57]. This evidence concerns the gene CD44 and colorectal carcinoma.